Incidence and Survival of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Cirrhosis Who Were Treated with and without Metformin
Thanida Tangjarusritaratorn,1 Watip Tangjittipokin,1,2 Tada Kunavisarut3 1Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 2Siriraj Center of Research Excellence in Diabetes and Obesity, Faculty of Medicine Siriraj Hospital, Mahidol University, B...
Guardado en:
Autores principales: | Tangjarusritaratorn T, Tangjittipokin W, Kunavisarut T |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/787f455f97a7478ba6323a62a4c54adf |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Alterations in the Gut Microbiome in the Progression of Cirrhosis to Hepatocellular Carcinoma
por: Yelena Lapidot, et al.
Publicado: (2020) -
Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application
por: Amir Mohamed Abdelhamid, et al.
Publicado: (2022) -
Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients
por: Magda Ibrahim, et al.
Publicado: (2020) -
Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin
por: Ng KJ, et al.
Publicado: (2016) -
Undifferentiated shock in a cirrhotic patient: Ascites matters
por: Antigoni Xenou, et al.
Publicado: (2021)